세계의 칼시뉴린 억제제 시장 보고서(2025년)

Calcineurin inhibitors (CNIs) are a class of immunosuppressant drugs that function by inhibiting calcineurin, a key enzyme involved in T-cell activation, thereby reducing immune responses. These drugs are primarily used to prevent organ transplant rejection and to treat autoimmune diseases such as psoriasis and atopic dermatitis. The most commonly used CNIs are cyclosporine and tacrolimus, both of which block the production of interleukin-2 (IL-2), a vital cytokine for T-cell proliferation.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main forms of calcineurin inhibitors are branded and generic versions. Branded calcineurin inhibitors are patented immunosuppressant drugs marketed under specific trade names by pharmaceutical companies. These are available in various dosages, including tablets, capsules, ointments, injections, and other forms. They are used for organ transplantation, autoimmune diseases, and other conditions. The primary end users of these drugs include hospitals, homecare settings, and pharmacies.

The calcineurin inhibitors market research report is one of a series of new reports from The Business Research Company that provides calcineurin inhibitors market statistics, including calcineurin inhibitors industry global market size, regional shares, competitors with a calcineurin inhibitors market share, detailed calcineurin inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the calcineurin inhibitors industry. This calcineurin inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The calcineurin inhibitors market size has grown strongly in recent years. It will grow from$8.84 billion in 2024 to $9.58 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to factors such as faster regulatory approvals for immunosuppressants, favorable reimbursement policies for transplant medications, increasing government support for organ transplantation, the expansion of healthcare infrastructure, and the growth of specialty pharmacies distributing immunosuppressants.

The calcineurin inhibitors market size is expected to see strong growth in the next few years. It will grow to$13.10 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth during the forecast period can be attributed to factors such as the expanding calcineurin inhibitors market, the rising prevalence of autoimmune diseases, an increase in chronic kidney disease cases leading to more transplants, a higher incidence of atopic dermatitis and psoriasis, and a growing patient pool for immunosuppressive therapies. Key trends during this period include advancements in drug formulations for improved efficacy, the development of extended-release formulations, research into combination therapies with calcineurin inhibitors, innovations in drug delivery methods, and a better understanding of T-cell signaling pathways.

The growing number of organ transplants is expected to drive the expansion of the calcineurin inhibitors market. Organ transplants involve the surgical replacement of a damaged or failing organ with a healthy one from a donor. The incidence of organ transplants is rising due to the increasing prevalence of chronic diseases such as diabetes and hypertension, which often lead to organ failure and heighten the demand for transplants. Calcineurin inhibitors play a crucial role in organ transplantation by inhibiting T-cell activation, preventing the immune system from recognizing the transplanted organ as foreign, and reducing the risk of rejection. This enhances the long-term survival of the graft. For example, in January 2025, the Organ Procurement and Transplantation Network (OPTN), a U.S.-based transplant information database, reported that organ transplants exceeded 48,000 in 2024, reflecting a 3.3% increase compared to 2023. Therefore, the rise in organ transplant procedures is fueling the growth of the calcineurin inhibitors market.

Key players in the calcineurin inhibitors market are concentrating on the development of immunosuppressive therapies, including treatments for autoimmune diseases, aimed at controlling excessive immune responses, reducing inflammation, and preventing tissue damage. These therapies, which include corticosteroids, immunosuppressants, biologics, and disease-modifying antirheumatic drugs (DMARDs), help regulate the immune system by suppressing overactive immune responses. For example, in April 2024, Biocon Limited, an India-based biopharmaceutical company, received approval from the South African Health Products Regulatory Authority (SAHPRA) for Tacrolimus, a calcineurin inhibitor and immunosuppressant used to prevent organ rejection in transplant patients. Tacrolimus has been effective in renal transplants for over two decades. It works by binding to the immunophilin FKBP-12, forming a complex that inhibits calcineurin activity, reducing the production of interleukin-2 (IL-2) and T-cell proliferation, which are crucial in the immune response against transplanted organs.

In July 2023, Harrow Inc., a U.S.-based eyecare pharmaceutical company, acquired Santen's branded ophthalmic portfolio for an undisclosed amount. The acquisition provided Harrow with commercial rights to six branded products from Santen, including VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a calcineurin inhibitor used to treat vernal keratoconjunctivitis (VKC) in both children and adults, with orphan-drug exclusivity. This acquisition strengthens Harrow's position in the U.S. ophthalmic pharmaceutical market and supports its strategy to become a leading industry player while significantly expanding its branded product offerings. Santen Pharmaceutical Co. Ltd., based in Japan, is a key manufacturer of calcineurin inhibitors.

Major players in the calcineurin inhibitors market are Pfizer Inc., Roche Holding AG, Bristol-Myers Squibb Company, Novartis AG, Viatris Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Huadong Medicine Co. Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Pharmaceutical Inc., Zydus Cadila, Biocon Limited, Glenmark Pharmaceuticals Ltd., Accord Healthcare Ltd., Strides Pharma Science Limited, Harrow Inc., and Panacea Biotec Ltd.

North America was the largest region in the calcineurin inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calcineurin inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the calcineurin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The calcineurin inhibitors market consists of sales of topical formulations and diagnostic and monitoring tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Calcineurin Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on calcineurin inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for calcineurin inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The calcineurin inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Branded; Generic
• 2) By Dosage: Tablets And Capsules; Ointments; Injections; Other Dosages
• 3) By Indication: Organ Transplantation; Autoimmune Disease; Other Indications
• 4) By End User: Hospitals; Homecare Settings; Pharmacies
• Subsegments:
• 1) By Branded: Patented Drugs; Proprietary Formulations
• 2) By Generic: Off-Patent Equivalents; Biosimilars
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Bristol-Myers Squibb Company; Novartis AG; Viatris Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Calcineurin Inhibitors Market Characteristics

3. Calcineurin Inhibitors Market Trends And Strategies

4. Calcineurin Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Calcineurin Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Calcineurin Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Calcineurin Inhibitors Market Growth Rate Analysis
• 5.4. Global Calcineurin Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Calcineurin Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Calcineurin Inhibitors Total Addressable Market (TAM)

6. Calcineurin Inhibitors Market Segmentation

• 6.1. Global Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded
• Generic
• 6.2. Global Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets And Capsules
• Ointments
• Injections
• Other Dosages
• 6.3. Global Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Organ Transplantation
• Autoimmune Disease
• Other Indications
• 6.4. Global Calcineurin Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare Settings
• Pharmacies
• 6.5. Global Calcineurin Inhibitors Market, Sub-Segmentation Of Branded, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Patented Drugs
• Proprietary Formulations
• 6.6. Global Calcineurin Inhibitors Market, Sub-Segmentation Of Generic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Off-Patent Equivalents
• Biosimilars

7. Calcineurin Inhibitors Market Regional And Country Analysis

• 7.1. Global Calcineurin Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Calcineurin Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Calcineurin Inhibitors Market

• 8.1. Asia-Pacific Calcineurin Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Calcineurin Inhibitors Market

• 9.1. China Calcineurin Inhibitors Market Overview
• 9.2. China Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Calcineurin Inhibitors Market

• 10.1. India Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Calcineurin Inhibitors Market

• 11.1. Japan Calcineurin Inhibitors Market Overview
• 11.2. Japan Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Calcineurin Inhibitors Market

• 12.1. Australia Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Calcineurin Inhibitors Market

• 13.1. Indonesia Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Calcineurin Inhibitors Market

• 14.1. South Korea Calcineurin Inhibitors Market Overview
• 14.2. South Korea Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Calcineurin Inhibitors Market

• 15.1. Western Europe Calcineurin Inhibitors Market Overview
• 15.2. Western Europe Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Calcineurin Inhibitors Market

• 16.1. UK Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Calcineurin Inhibitors Market

• 17.1. Germany Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Calcineurin Inhibitors Market

• 18.1. France Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Calcineurin Inhibitors Market

• 19.1. Italy Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Calcineurin Inhibitors Market

• 20.1. Spain Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Calcineurin Inhibitors Market

• 21.1. Eastern Europe Calcineurin Inhibitors Market Overview
• 21.2. Eastern Europe Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Calcineurin Inhibitors Market

• 22.1. Russia Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Calcineurin Inhibitors Market

• 23.1. North America Calcineurin Inhibitors Market Overview
• 23.2. North America Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Calcineurin Inhibitors Market

• 24.1. USA Calcineurin Inhibitors Market Overview
• 24.2. USA Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Calcineurin Inhibitors Market

• 25.1. Canada Calcineurin Inhibitors Market Overview
• 25.2. Canada Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Calcineurin Inhibitors Market

• 26.1. South America Calcineurin Inhibitors Market Overview
• 26.2. South America Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Calcineurin Inhibitors Market

• 27.1. Brazil Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Calcineurin Inhibitors Market

• 28.1. Middle East Calcineurin Inhibitors Market Overview
• 28.2. Middle East Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Calcineurin Inhibitors Market

• 29.1. Africa Calcineurin Inhibitors Market Overview
• 29.2. Africa Calcineurin Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Calcineurin Inhibitors Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Calcineurin Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Calcineurin Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Calcineurin Inhibitors Market Competitive Landscape
• 30.2. Calcineurin Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Calcineurin Inhibitors Market Other Major And Innovative Companies

• 31.1. Astellas Pharma Inc.
• 31.2. Bausch Health Companies Inc.
• 31.3. Huadong Medicine Co. Ltd.
• 31.4. Sun Pharmaceutical Industries Ltd.
• 31.5. Apotex Inc.
• 31.6. Dr. Reddy's Laboratories Ltd.
• 31.7. Cipla Ltd.
• 31.8. Lupin Pharmaceutical Inc.
• 31.9. Zydus Cadila
• 31.10. Biocon Limited
• 31.11. Glenmark Pharmaceuticals Ltd.
• 31.12. Accord Healthcare Ltd.
• 31.13. Strides Pharma Science Limited
• 31.14. Harrow Inc.
• 31.15. Panacea Biotec Ltd.

32. Global Calcineurin Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Calcineurin Inhibitors Market

34. Recent Developments In The Calcineurin Inhibitors Market

35. Calcineurin Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Calcineurin Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Calcineurin Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Calcineurin Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34788_Calcineurin_Inhibitors_GMR_2025